Largest biotech companies by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech companies ranked by net assets, at SAR 85.2B, ahead of BioNTech (SAR 80B) and Biogen (SAR 68.5B). Figures as of 18 Nov 2026, 17:47 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesSAR 85.2B
- Median
- SAR 7.6B
- Combined market value
- SAR 3.16T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | SAR 85.2B | SAR 787.6B | SAR 634.99 | 0.57% down | 33% up | ||
| 2 | BioNTechBNTX · Health Care | SAR 80B | SAR 78.3B | SAR 315.80 | 0.79% down | 16% down | ||
| 3 | BiogenBIIB · Health Care | SAR 68.5B | SAR 139.7B | SAR 945.36 | 0.49% up | 49% up | ||
| 4 | AmgenAMGN · Health Care | SAR 32.5B | SAR 905.8B | SAR 1,674.67 | 2.50% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | SAR 32.4B | SAR 307.9B | SAR 760.87 | 1.91% down | 755% up | ||
| 6 | argenxARGX · Health Care | SAR 27.5B | SAR 223.2B | SAR 3,548.86 | 0.15% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | SAR 14.2B | SAR 38.4B | SAR 186.20 | 0.22% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SAR 12.2B | SAR 61.7B | SAR 609.80 | 2.02% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | SAR 10.1B | SAR 35.1B | SAR 221.48 | 0.60% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | SAR 8.1B | SAR 63.3B | SAR 259.49 | 0.99% up | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | SAR 7.9B | SAR 42.9B | SAR 273.00 | 0.21% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | SAR 7.9B | SAR 41.4B | SAR 647.12 | 6.38% up | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | SAR 7.2B | SAR 15.3B | SAR 157.84 | 4.81% up | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | SAR 6.1B | SAR 129.8B | SAR 600.22 | 1.64% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | SAR 5.9B | SAR 39.2B | SAR 458.71 | 0.63% up | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | SAR 4.6B | SAR 34.9B | SAR 1,177.63 | 5.16% up | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | SAR 3.2B | SAR 26.1B | SAR 126.15 | 1.26% up | 43% up | ||
| 18 | CG OncologyCGON · Health Care | SAR 2.8B | SAR 27.3B | SAR 306.10 | 3.38% up | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | SAR 1.8B | SAR 30.1B | SAR 441.79 | 5.16% up | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | SAR 920.8M | SAR 21.7B | SAR 177.57 | 5.01% up | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | SAR 820.7M | SAR 17.4B | SAR 107.54 | 0.63% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | SAR 590.3M | SAR 24B | SAR 366.40 | 0.91% up | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | SAR 183.1M | SAR 41.4B | SAR 362.76 | 0.77% up | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -SAR 1.9B | SAR 26.9B | SAR 25.24 | 7.51% up | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech companies rank first by net assets?
Gilead Sciences (SAR 85.2B), BioNTech (SAR 80B) and Biogen (SAR 68.5B) are the top three of the 24 biotech companies ranked by net assets as of 18 Nov 2026, 17:47 UTC.
How many biotech companies are in this ranking?
24 are ranked by net assets.
What are these biotech companies worth together?
The 24 biotech companies ranked by net assets have a combined market value of SAR 3.16T as of 18 Nov 2026, 17:47 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.